Alpha Tau reports 11.2-month median survival in pooled Phase I/II Alpha DaRT pancreatic cancer studies at ASCO 2026

• Alpha Tau Medical reported overall survival results from pooled early-stage pancreatic cancer studies, presented at the 2026 ASCO Annual Meeting.
• Findings indicated patients lived longer than expected across several prior-treatment settings, supporting the therapy’s potential clinical benefit.
• Safety was described as favorable, with limited severe side effects, no treatment-related deaths, no chronic toxicity reported.
• Focus now shifts to completing enrollment in the U.S. IMPACT trial testing Alpha DaRT with first-line chemotherapy in newly diagnosed unresectable disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-063182), on June 01, 2026, and is solely responsible for the information contained therein.